Tourmaline Bio, Inc. (TRML)
Oct 28, 2025 - TRML was delisted (reason: acquired by NVS)
47.98
0.00 (0.00%)
Inactive · Last trade price
on Oct 27, 2025
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Tourmaline Bio stock had an average target of 49.05, with a low estimate of 47.5 and a high estimate of 58.
Price Target: $49.05 (+2.23%)
Analyst Consensus: Hold
* Price targets were last updated on Sep 15, 2025.
Analyst Ratings
The average analyst rating for Tourmaline Bio stock from 12 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Suspends n/a | Buy | Suspends | n/a | n/a | Oct 29, 2025 |
| BMO Capital | BMO Capital | Buy → Hold Downgrades $35 → $48 | Buy → Hold | Downgrades | $35 → $48 | +0.04% | Sep 15, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $65 → $48 | Buy → Hold | Downgrades | $65 → $48 | +0.04% | Sep 11, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $63 → $48 | Strong Buy → Hold | Downgrades | $63 → $48 | +0.04% | Sep 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades $55 → $48 | Strong Buy → Hold | Downgrades | $55 → $48 | +0.04% | Sep 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.83
from -2.89
EPS Next Year
-4.17
from -3.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.78 | -3.56 | |||
| Avg | -3.83 | -4.17 | |||
| Low | -4.01 | -4.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.